Limits...
A single 80 mg intravenous gentamicin dose prior to prostate needle biopsy does not reduce procedural infectious complications.

Raman JD, Rjepaj C, Otteni C - Cent European J Urol (2015)

Bottom Line: The incidence of infections post-biopsy was compared between patients receiving oral alone versus IV plus oral antibiotic prophylaxis. 182 of 522 men (34.9%) included in this study received peri-procedural IV gentamicin at time of TRUS PNB, with a significant increase in utilization during the study time period (p <0.001).In total, 39 patients (7.5%) developed an infectious complication post-biopsy.In this 4-year cohort analysis, a single peri-procedural dose of 80 mg of intravenous gentamicin failed to confer a reduction in infectious complications following prostate needle biopsy.

View Article: PubMed Central - PubMed

Affiliation: Penn State Milton S. Hershey Medical Center, Department of Urology, Hershey, USA.

ABSTRACT

Introduction: Rates of infectious complications continue to increase following transrectal ultrasound guided prostate needle biopsy (TRUS PNB). Administration of a parenteral antibiotic at time of procedure represents one potential prophylaxis strategy. The efficacy of this practice remains incompletely defined.

Material and methods: Our institutional TRUS PNB database was reviewed to identify consecutive men undergoing a biopsy over a 48-month period. The peri-operative intravenous antibiotic regimen (when used) included gentamicin 80 mg administered intravenously (IV) 30 minutes prior to biopsy. The incidence of infections post-biopsy was compared between patients receiving oral alone versus IV plus oral antibiotic prophylaxis.

Results: 182 of 522 men (34.9%) included in this study received peri-procedural IV gentamicin at time of TRUS PNB, with a significant increase in utilization during the study time period (p <0.001). In total, 39 patients (7.5%) developed an infectious complication post-biopsy. No differences in infection rates were observed between patients receiving only oral prophylaxis (27 of 340, 7.9%) versus those receiving oral with IV gentamicin (12 of 182, 6.6%) (p = 0.73).

Conclusions: In this 4-year cohort analysis, a single peri-procedural dose of 80 mg of intravenous gentamicin failed to confer a reduction in infectious complications following prostate needle biopsy. Such data underscore the need to better understand the dose, route, and type of antimicrobial therapy to limit procedural infections.

No MeSH data available.


Related in: MedlinePlus

Rates of utilization of intravenous gentamicin over a 4-year period at time of transrectal ultrasound guided prostate needle biopsy.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4526609&req=5

Figure 0001: Rates of utilization of intravenous gentamicin over a 4-year period at time of transrectal ultrasound guided prostate needle biopsy.

Mentions: Of 522 men in the cohort, 182 (34.9%) received peri-procedural IV 80 mg gentamicin at the time of TRUS PNB, including 26 of 142 (18%) in year 1, 36 of 132 (27%) in year 2, 50 of 121 (41%) in year 3, and 70 of 128 (55%) in year 4. Compared to the initial year of study, utilization of IV gentamicin rose significantly in year 3 and 4 (p <0.001 for both) with a trend to significance at year 2 (p = 0.08) (Figure 1).


A single 80 mg intravenous gentamicin dose prior to prostate needle biopsy does not reduce procedural infectious complications.

Raman JD, Rjepaj C, Otteni C - Cent European J Urol (2015)

Rates of utilization of intravenous gentamicin over a 4-year period at time of transrectal ultrasound guided prostate needle biopsy.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4526609&req=5

Figure 0001: Rates of utilization of intravenous gentamicin over a 4-year period at time of transrectal ultrasound guided prostate needle biopsy.
Mentions: Of 522 men in the cohort, 182 (34.9%) received peri-procedural IV 80 mg gentamicin at the time of TRUS PNB, including 26 of 142 (18%) in year 1, 36 of 132 (27%) in year 2, 50 of 121 (41%) in year 3, and 70 of 128 (55%) in year 4. Compared to the initial year of study, utilization of IV gentamicin rose significantly in year 3 and 4 (p <0.001 for both) with a trend to significance at year 2 (p = 0.08) (Figure 1).

Bottom Line: The incidence of infections post-biopsy was compared between patients receiving oral alone versus IV plus oral antibiotic prophylaxis. 182 of 522 men (34.9%) included in this study received peri-procedural IV gentamicin at time of TRUS PNB, with a significant increase in utilization during the study time period (p <0.001).In total, 39 patients (7.5%) developed an infectious complication post-biopsy.In this 4-year cohort analysis, a single peri-procedural dose of 80 mg of intravenous gentamicin failed to confer a reduction in infectious complications following prostate needle biopsy.

View Article: PubMed Central - PubMed

Affiliation: Penn State Milton S. Hershey Medical Center, Department of Urology, Hershey, USA.

ABSTRACT

Introduction: Rates of infectious complications continue to increase following transrectal ultrasound guided prostate needle biopsy (TRUS PNB). Administration of a parenteral antibiotic at time of procedure represents one potential prophylaxis strategy. The efficacy of this practice remains incompletely defined.

Material and methods: Our institutional TRUS PNB database was reviewed to identify consecutive men undergoing a biopsy over a 48-month period. The peri-operative intravenous antibiotic regimen (when used) included gentamicin 80 mg administered intravenously (IV) 30 minutes prior to biopsy. The incidence of infections post-biopsy was compared between patients receiving oral alone versus IV plus oral antibiotic prophylaxis.

Results: 182 of 522 men (34.9%) included in this study received peri-procedural IV gentamicin at time of TRUS PNB, with a significant increase in utilization during the study time period (p <0.001). In total, 39 patients (7.5%) developed an infectious complication post-biopsy. No differences in infection rates were observed between patients receiving only oral prophylaxis (27 of 340, 7.9%) versus those receiving oral with IV gentamicin (12 of 182, 6.6%) (p = 0.73).

Conclusions: In this 4-year cohort analysis, a single peri-procedural dose of 80 mg of intravenous gentamicin failed to confer a reduction in infectious complications following prostate needle biopsy. Such data underscore the need to better understand the dose, route, and type of antimicrobial therapy to limit procedural infections.

No MeSH data available.


Related in: MedlinePlus